George Chaldakov
From Wikipedia, the free encyclopedia
George Nikov Chaldakov (born February 23, 1940, in Burgas, Bulgaria) is a Bulgarian vascular biologist well-known for his contributions in the study of secretory function of vascular smooth muscle cells, and the role of neurotrophins and perivascular adipose tissue in pathogenesis of atherosclerosis. He published the first Bulgarian textbook of Cell Biology in 1996 and in 2005 founded the Bulgarian Society for Cell Biology.
In 1966 graduated as MD from Varna Institute of Medicine (since 1991, named Medical University of Varna), Varna, Bulgaria.
In 1983 obtained PhD degree in Vascular Biology, "Ultrastructural and cytopharmacological study of aging in vascular smooth muscle cells, with special reference to their secretory function".
In the past 30 years George Chaldakov was involved in an interdisciplinary research in the fields of vascular biology, adipobiology and neurobiology and is one of the pioneers establishing the novel concept of the secretory function/phenotype of the vascular smooth muscle cells and further delineating their role in atherogenesis. In collaboration with Luigi Aloe has been developed a complex tripartite model of atherogenesis in which are involved smooth muscle cells, immune cells, and perivascular adipose tissue communicating through secreted factors (e.g. neurotrophins, adipokines, cytokines).
George Chaldakov is main editor and founder in 1991 of Biomedical Reviews, An International Journal of Cell Biology of Disease and organizer of Biomedical Forum, Annual Program of Continuing Medical Education held at Medical University of Varna, Bulgaria.
[edit] Innovations and substantial contributions to science
- Concept of the secretory function/phenotype of the vascular smooth muscle cell, as related to atherogenesis.[1][2][3]
- Tubulin/microtubule-targeted pharmacology for atherosclerosis.[4][5][6]
- Concept of the neurotrophins NGF and BDNF as metabotrophic factors (metabotrophins) in cardiometabolic biology/diseases.[7][8]
- Conceptualize the protein secretory products of adipose tissue cells as adipokines, also focusing on perivascular adipose tissue.[9][10][11]
- In 2006 introduced the term Homo obesus and is actively involved in popularizing the need of healthy lifestyle and dietary restriction: millions of people suffer and die from starvation in ill-developed and poor countries while in Western civilization and Europe people get overweight and die as a result of strokes or heart infarctions.[15]
[edit] References and notes
- ^ Chaldakov GN, Nikolov SD (1975). "Ultrastructure of the arterial smooth muscle cell". In: Smooth Muscle of the Artery. Plenum Press, New York, London etc. Advances in Experimental Medicine and Biology 57: 14–20.
- ^ Chaldakov GN, Nikolov SD, Vankov VN (1977). "Fine morphological aspects of the secretory process of arterial smooth muscle cells. II. Role of microtubules". Acta Morphologica Academiae Scientiarum Hungaricae 25: 167–174.
- ^ Chaldakov GN, Vankov VN (1986). "Morphological aspects of secretion in the arterial smooth muscle cell, with special reference to the Golgi complex and microtubular cytoskeleton". Atherosclerosis 61: 175–192. doi:.
- ^ Chaldakov GN (1982). "Antitubulins - a new therapeutic approach for atherosclerosis?". Atherocslerosis 44: 385–390. doi:.
- ^ Chaldakov GN, Vankov VN (1986). "Antifibrotic approach in the therapy of arterial occlusive diseases: new considerations". In: Conservative Therapy of Arterial Occlusive Disease, G. Trubestein (ed.), Stuttgart, New York, Georg Thieme Verlag: pp.224–226.
- ^ Chaldakov GN (1991). "Anti-inflammatory drugs and ischemic heart disease: new considerations (a cell biologist's proposal to cardiologists)". Journal of The American College of Cardiology 17: 1445–1446.
- ^ Chaldakov GN, Fiore M, Hristova M, Aloe L (2003). "Metabotrophic potential of neurotrophins: implication in obesity and related diseases?". Medical Science Monitor 21: HY19–21.
- ^ Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L (2005). "Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes". International Journal of Cardiology 102: 169–171. doi:.
- ^ Chaldakov GN, Fiore M, Ghenev PI, Stankulov IS. Aloe L (2000). "Atherosclerotic lesions: possible interactive involvement of intima, adventitia and associated adipose tissue". The International Medical Journal 7: 43–49.
- ^ Chaldakov GN, Stankulov IS, Aloe L (2001). "Subepicardial adipose tissue in human coronary atherosclerosis: another neglected phenomenon". Atherosclerosis 154: 237–238. doi:.
- ^ Chaldakov GN, Stankulov IS, Fiore M, Ghenev PI, Aloe L (2001). "Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis". Atherosclerosis 159: 57–66. doi:.
- ^ Chaldakov GN, Stankulov IS, Hristova MG, Ghenev PI (2003). "Adipobiology of disease: adipokines and adipokine-targeted pharmacology". Current Pharmaceutical Design 9: 1023–1031. doi:.
- ^ Chaldakov GN, Fiore M, Hristova M, Aloe L (2000). "Cell biology and pharmacology of adipose tissue secretion". FABAD Journal of Pharmaceutical Sciences 25: 181–191.
- ^ Chaldakov GN, Fiore M, Tonchev AB, Aloe L (2006). "Adipopharmacology, a novel drug discovery approach: a metabotrophic perspective". Letters in Drug Design & Discovery 3: 503–505.
- ^ Chaldakov GN (2006). "State-of-the-heart: Homo obesus and human heart health". http://www.worldheart.org.
